Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: Proof from the "biological window therapy"

Breast Cancer Research and Treatment

Volumn 144, Issue 1, 2014, Pages 113-121

  Foroni, Chiara ^a   Milan, Manuela ^a   Strina, Carla ^a   Cappelletti, Mariarosa ^a   Fumarola, Claudia ^d   Bonelli, Mara ^d   Bertoni, Ramona ^c   Ferrero, Giuseppina ^c   Maldotti, Mara ^a   Takano, Elena ^g   Andreis, Daniele ^a   Venturini, Sergio ^b   Brugnoli, Giulia ^a   Petronini, Pier Giorgio ^d   Zanoni, Vanessa ^a   Pritzker, Laura ^e   Pritzker, Kenneth ^e   Parissenti, Amadeo ^h   Santini, Daniele ^f   Fox, Stephen B ^g   Bottini, Alberto ^a   Generali, Daniele ^a   more..

^a UO Multidisciplinare di Patologia Mammaria   (Italy)

^b BOCCONI UNIVERSITY   (Italy)

^c Anatomia Patologica   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e Rna Diagnostics Inc   (Canada)

^f UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h LAURENTIAN UNIVERSITY   (Canada)

Author keywords

Breast cancer; Circulating tumor cells; Ki67; Window therapy; Zoledronic acid

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 3; CD34 ANTIGEN; CELL MARKER; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL THERAPY; BIOLOGICAL WINDOW THERAPY; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER TISSUE; CELL COUNT; CELL DEATH; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL PROTOCOL; ENZYME BLOOD LEVEL; FEMALE; GENETIC PARAMETERS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RNA DISRUPTION INDEX; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING;

EID: 84894674807     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2840-y     Document Type: Article

References (41)

1. Manders K, van de Poll-Franse LV, Creemers GJ, Vreugdenhil G, van der Sangen MJ, Nieuwenhuijzen GA et al (2006) Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer 6:179
2. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525-533
3. Cristofanilli M (2006) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol 33:S9-S14
4. Sceneay J, Smyth MJ, Moller A (2013) The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. doi: 10.1007/s10555-013-9420-1
5. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6:2609-2617
6. Zoccoli A, Iuliani M, Pantano F, Imperatori M, Intagliata S, Vincenzi B et al (2012) Premetastatic niche: ready for new therapeutic interventions? Expert Opin Ther Targets 16(Suppl 2):S119-S129
7. Clezardin P (2005) Anti-tumour activity of zoledronic acid. Cancer Treat Rev 31(Suppl 3):1-8
8. Gnant M, Clezardin P (2012) Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev 38:407-415
9. Neville-Webbe HL, Evans CA, Coleman RE, Holen I (2006) Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 27:92-103
10. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100:1167-1178
11. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893-2897
12. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84:1126-1134
13. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384-392
14. Aft R, Perez JR, Raje N, Hirsh V, Saad F (2012) Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates. Crit Rev Oncol Hematol 82:233-248
15. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM et al (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102:1099-1105
16. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C et al (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631-641
17. Coleman R, Gnant M, Morgan G, Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104:1059-1067
18. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S et al (2001) Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 85:1106-1112
19. Nakopoulou L, Alexandrou P, Stefanaki K, Panayotopoulou E, Lazaris AC, Davaris PS (2001) Immunohistochemical expression of caspase-3 as an adverse indicator of the clinical outcome in human breast cancer. Pathobiology 69:266-273
20. Fumarola C, La Monica S, Guidotti GG (2005) Amino acid signaling through the mammalian target of rapamycin (mTOR) pathway: role of glutamine and of cell shrinkage. J Cell Physiol 204:155-165
21. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791
22. Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M et al (2010) M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by Cell Search analysis. Clin Cancer Res 16:5233-5243
23. Come PC, Come SE, Hawley CR, Gwon N, Riley MF (1982) Echocardiographic manifestations of carcinoid heart disease. J Clin Ultrasound 10:233-237
24. Coleman RE, McCloskey EV (2011) Bisphosphonates in oncology. Bone 49:71-76
25. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396-1405
26. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691
27. Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE et al (2013) Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer-a randomized biomarker pilot study. Clin Cancer Res 19:2755-2765
28. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656-1664
29. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I (2009) Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 8:2821-2832
30. Brenner C, Grimm S (2006) The permeability transition pore complex in cancer cell death. Oncogene 25:4744-4756
31. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G (2006) Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 13:1423-1433
32. Cande C, Cohen I, Daugas E, Ravagnan L, Larochette N, Zamzami N et al (2002) Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie 84:215-222
33. Kuroda J, Kimura S, Segawa H, Sato K, Matsumoto S, Nogawa M et al (2004) p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. Cancer Sci 95:186-192
34. Fehm T, Zwirner M, Wallwiener D, Seeger H, Neubauer H (2012) Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer 12:308
35. Solomayer EF, Gebauer G, Hirnle P, Janni W, Luck HJ, Becker S et al (2012) Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 23:2271-2277
36. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M (2000) Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89:2145-2152
37. Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S et al (2003) Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 89:1035-1041
38. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75-85
39. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S et al (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228-1236
40. Cummings J, Ward TH, LaCasse E, Lefebvre C, St-Jean M, Durkin J et al (2005) Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 92:532-538
41. Leist M, Single B, Naumann H, Fava E, Simon B, Kuhnle S et al (1999) Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis. Exp Cell Res 249:396-403